Biovica International AB (publ) (STO:BIOVIC.B)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.291
+0.016 (5.82%)
Mar 9, 2026, 5:01 PM CET
-84.65%
Market Cap 84.95M
Revenue (ttm) 9.89M
Net Income (ttm) -76.47M
Shares Out 291.91M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 396,495
Average Volume 334,462
Open 0.295
Previous Close 0.275
Day's Range 0.270 - 0.295
52-Week Range 0.270 - 2.000
Beta 1.28
RSI 29.63
Earnings Date Mar 18, 2026

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol BIOVIC.B
Full Company Profile

Financial Performance

In fiscal year 2025, Biovica International AB's revenue was 8.65 million, an increase of 18.53% compared to the previous year's 7.30 million. Losses were -87.62 million, -29.80% less than in 2024.

Financial Statements

News

There is no news available yet.